MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1505 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

59 trials at this site

Phase	Trial	Trial Status [desc]	Site Status	Drug	NCT#
1	Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma	Ongoing, but not recruiting	Closed	PXD101	NCT00413075
1	Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678223
1	IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678769
1	Phase 1 Study of Intermittent OSI-906 Dosing	Ongoing, but not recruiting	Closed	Linsitinib (OSI-906)	NCT00514306
1	Administration of BIIB028 to Subjects With Solid Tumors	Ongoing, but not recruiting	Closed	BIIB028	NCT00725933
1	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer	Ongoing, but not recruiting	Closed	BEZ235	NCT00620594
1	Phase I Study of Pazopanib and Vorinostat	Ongoing, but not recruiting	Closed	Pazopanib (Votrient) + vorinostat (Zolinza)	NCT01339871
1	Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BEZ235 + MEK162	NCT01337765
1	A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + GSK1120212	NCT01155453
1	Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	Ongoing, but not recruiting	Closed	Pazopanib + Trametinib	NCT01438554
1	Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ongoing, but not recruiting	Closed	BAY80-6946 + BAY86-9766	NCT01392521
	Symptom Inventory for Gastrointestinal Stromal Tumors	Ongoing, but not recruiting	Closed		NCT01178307
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
2	Ph II Study of Perifosine Plus Gleevec for Patients With GIST	Completed	Closed	Imatinib + Perifosine	NCT00455559
2	Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST (MDACC)	Completed	Closed	Imatinib	NCT00500188
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Not yet activated	Linsitinib (OSI-906)	NCT01560260

MD Anderson Cancer Center

59 trials at this site

First | Previous | Page 2 of 3 | Next | Last